DOJ Doubles Down on Healthcare Fraud Enforcement with New West Coast Strike Force

The Department of Justice’s new “West Coast” strike force targets Arizona, Nevada and Northern California — regions flagged for rising Medicaid, hospice and tech-enabled fraud risks. Legal experts say the effort signals a broader shift toward data-driven enforcement, as regulators ramp up their scrutiny of telehealth companies and billing automation software. The post DOJ Doubles…

Read More

Why We’re Still Finding Cancer Too Late

The truth is there are ways to understand our cancer risk more precisely than we do today, and there are tools to manage it. What’s missing is awareness, access, and a system built to help us use these tools before something goes wrong. The post Why We’re Still Finding Cancer Too Late appeared first on…

Read More

The rise in fabricated citations

From a Topaz et al. (2026) paper in The Lancet reviewing citations across 2.5 peer-reviewed papers in PubMed: Among 97·1 million verified references, we identified 4046 fabricated references across 2810 papers (illustrative examples are shown in the appendix p 5–6). In 2023, approximately one in 2828 papers contained at least one fabricated reference. By 2025,…

Read More

Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors

Pennsylvania sued Character.ai, alleging one of the startup’s AI chatbots illegally practiced medicine by posing as a licensed psychiatrist. The case marks the second state lawsuit against the startup and highlights growing regulatory scrutiny of AI chatbot platforms and their safety guardrails. The post Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors appeared first on…

Read More

Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs

Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally discovered lead drug candidate. With the IPO proceeds, Odyssey plans mid-stage clinical trials evaluating the small molecule in combination with Takeda’s Entyvio and as a monotherapy. The post Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs appeared first on MedCity News.

Read More